SCHEMBL16340656

CC(=O)N[C@H]1CCCNC(=O)C[C@@H](C(=O)N2CCC[C@H]2C(=O)N2CCC[C@H]2C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN(CC(=O)O)CC(=O)O)C(=O)N[C@@H](CCCCNC(=O)COCCOCCNC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(N)=O)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O

nearest known ligand 0.53

Predicted protein targets (top 4)

	gene	UniProt	supporting neighbours	confidence
▸	MDM2	Q00987	4/20	0.53

▸	IL23R	Q5VWK5	10/20	0.52

▸	MC4R	P32245	5/20	0.51

▸	GLP1R	P43220	1/20	0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL14552623	1.00	MDM2 (0.53)	MDM2IL23RMC4RGLP1R
SCHEMBL14552854	1.00	MDM2 (0.53)	MDM2IL23RMC4RGLP1R
SCHEMBL14550322	0.99	MDM2 (0.53)	MDM2IL23RMC4RGLP1R
SCHEMBL16340396	0.99	IL23R (0.52)	MDM2IL23RMC4R
SCHEMBL16340624	0.99	IL23R (0.52)	MDM2IL23RMC4R
SCHEMBL14550326	0.98	MDM2 (0.55)	MDM2IL23RMC4RGLP1R
SCHEMBL16340741	0.97	MDM2 (0.56)	MDM2IL23RMC4RGLP1R
SCHEMBL14552772	0.97	IL23R (0.52)	MDM2IL23RMC4RGLP1R
SCHEMBL16340667	0.97	IL23R (0.51)	MDM2IL23RMC4R
SCHEMBL14550274	0.96	IL23R (0.52)	MDM2IL23RMC4RGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20130012432-A1	Peptides for Treatment of Obesity	NOVO NORDISK A/S (DK)	2013-01-10	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20130012432-A1	Peptides for Treatment of Obesity	MC4R, GIPR, MC3R	MDM2 4657/4885IL23R 698/4885MC4R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.